
NYSE:UNH
This summary was created by AI, based on 41 opinions in the last 12 months.
UnitedHealth Group Inc (UNH) has faced significant challenges in the past year, including leadership changes, regulatory scrutiny, and headwinds from rising medical costs. Despite these issues, some analysts are optimistic about the long-term prospects, citing the company's strong position in the healthcare industry and the potential for recovery as costs are managed more effectively. There is a consensus that the return of a previous CEO could lead to better operational control, yet concerns about the future remain, particularly related to earnings projections and potential regulatory changes. While there are opinions on both sides regarding its current valuation, the stock has been seen as either undervalued or merely a defensive play amid turbulent market conditions.
Yes. It was a top pick of his last spring. He doesn't think there will be much negative impact from Washington investigating their billing practices, though there remains headline risk. Fundamentals are improving, though they are paying out more for medical costs, which he hopes will normalize. It's trading below the market PE, when usually it trades above.
It is integral to the systematic delivery of health care across the U.S. and is a leader in well vertically integrated companies. There are some headwinds which he thinks will dissipate. He likes the longer term prospects and is seeing the development of per capita growth.
Buy 29 Hold 1 Sell 0
He bought some yesterday. Didn't change guidance. Q4 profitability was OK, though revenue was a bit light. Health insurance in US will continue to grow, it's a leader. Core holding for him. Great distribution system, so cost is less than peers. Trump administration will not nationalize healthcare.
Well run and uses AI a lot. It's an easy punching bag in the US for critics of the healthcare system. Health is always a political hot knife, but HC is the biggest employer in the US. Some disagree, but it's not in their interest to screw customers (by denying claims). He has been this all the way down.
Low beta, more conservative name. Very significant scale. Far ahead of peers with strong alignment of medical insurance, pharmacy benefits, and healthcare services. Aging demographics are key drivers of demand. Shares are 19% off their highs, an opportunity. 18x PE for 11% growth. Yield is 1.7%.
(Analysts’ price target is $641.46)The entire US health insurance group is embroiled in a controversy that was unfortunately set off by the murder of UNH, specifically talk about how claims are treated at UNH. These stocks are falling, but hang on and let this pass and see how different parties react. There will always be a place for health insurance companies in the US.
It reports Thursday. Not too high of a PE and not overly loved and purely domestic. It has pricing power.